Talis Biomedical Triumphs: Reaches Nasdaq Minimum Bid Price Requirement

Talis Biomedical Corporation (Nasdaq: TLIS) is proud to announce that it has regained compliance with Nasdaq Listing Rule 5550(a)(2) after maintaining a closing bid price of at least $1.00 per share for a period of ten consecutive business days. This is a major milestone for the Company, as Nasdaq stated that it now considers the matter closed.

Talis Biomedical is devoted to advancing health equity and outcomes through the delivery of accurate infectious disease testing at the point of care, and this news only strengthens their dedication to provide the best possible service to their customers.

The Company’s 1-for-15 reverse stock split, which was approved by stockholders on June 9, 2023 and became effective at 5:00 p.m. Eastern time on July 5, 2023, has been successful in elevating the stock price to a minimum of $1.00 per share for the 10 consecutive business days ended July 19, 2023.

About Talis Biomedical

Talis Biomedical is committed to eliminating barriers to healthcare access and improving health outcomes with the introduction of their Talis One® system. This revolutionary molecular testing system is designed to provide rapid, accurate, and low cost infectious disease testing right at the point of care – no longer will waiting for lab results stand in the way of quality healthcare. Through the use of their state-of-the-art sample-to-answer system, Talis Biomedical is transforming the future of healthcare.

Leave a Comment